Giacomo Montagna1, Hersh V Gupta2, Margaret Hannum3, Kay See Tan3, Jasme Lee3, Joseph R Scarpa4, George Plitas1, Takeshi Irie5, Patrick J McCormick5, Gregory W Fischer5, Monica Morrow1, Joshua S Mincer6. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 2. Center for Computational Molecular Biology, Brown University, Providence, RI, USA. 3. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA. 5. Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA; Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Anesthesiology, Weill Cornell Medicine, New York, NY, USA; Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: mincerj@mskcc.org.
Abstract
BACKGROUND: Opioid-induced immunomodulation may be of particular importance in triple-negative breast cancer (TNBC) where an immune response is associated with improved outcome and response to immunotherapy. We evaluated the association between intraoperative opioids and oncological outcomes and explored patterns of opioid receptor expression in TNBC. METHODS: Consecutive patients with stage I-III primary TNBC were identified from a prospectively maintained database. Opioid receptor expression patterns in the tumour microenvironment were analysed using publicly available bulk and single-cell RNA-seq data. RESULTS: A total of 1143 TNBC cases were retrospectively analysed. In multivariable analysis, higher intraoperative opioid dose was associated with favourable recurrence-free survival, hazard ratio 0.93 (95% confidence interval 0.88-0.99) per 10 oral morphine milligram equivalents increase (P=0.028), but was not significantly associated with overall survival, hazard ratio 0.96 (95% confidence interval 0.89-1.02) per 10 morphine milligram equivalents increase (P=0.2). Bulk RNA-seq analysis of opioid receptors showed that OPRM1 was nearly non-expressed. Compared with normal breast tissue OGFR, OPRK1, and OPRD1 were upregulated, while TLR4 was downregulated. At a single-cell level, OPRM1 and OPRD1 were not detectable; OPRK1 was expressed mainly on tumour cells, whereas OGFR and TLR4 were more highly expressed on immune cells. CONCLUSIONS: We found a protective effect of intraoperative opioids on recurrence-free survival in TNBC. Opioid receptor expression was consistent with a net protective effect of opioid agonism, with protumour receptors either not expressed or downregulated, and antitumour receptors upregulated. In this era of personalised medicine, efforts to differentiate the effects of opioids across breast cancer subtypes (and ultimately individual patients) should continue.
BACKGROUND: Opioid-induced immunomodulation may be of particular importance in triple-negative breast cancer (TNBC) where an immune response is associated with improved outcome and response to immunotherapy. We evaluated the association between intraoperative opioids and oncological outcomes and explored patterns of opioid receptor expression in TNBC. METHODS: Consecutive patients with stage I-III primary TNBC were identified from a prospectively maintained database. Opioid receptor expression patterns in the tumour microenvironment were analysed using publicly available bulk and single-cell RNA-seq data. RESULTS: A total of 1143 TNBC cases were retrospectively analysed. In multivariable analysis, higher intraoperative opioid dose was associated with favourable recurrence-free survival, hazard ratio 0.93 (95% confidence interval 0.88-0.99) per 10 oral morphine milligram equivalents increase (P=0.028), but was not significantly associated with overall survival, hazard ratio 0.96 (95% confidence interval 0.89-1.02) per 10 morphine milligram equivalents increase (P=0.2). Bulk RNA-seq analysis of opioid receptors showed that OPRM1 was nearly non-expressed. Compared with normal breast tissue OGFR, OPRK1, and OPRD1 were upregulated, while TLR4 was downregulated. At a single-cell level, OPRM1 and OPRD1 were not detectable; OPRK1 was expressed mainly on tumour cells, whereas OGFR and TLR4 were more highly expressed on immune cells. CONCLUSIONS: We found a protective effect of intraoperative opioids on recurrence-free survival in TNBC. Opioid receptor expression was consistent with a net protective effect of opioid agonism, with protumour receptors either not expressed or downregulated, and antitumour receptors upregulated. In this era of personalised medicine, efforts to differentiate the effects of opioids across breast cancer subtypes (and ultimately individual patients) should continue.
Authors: Abraham M Tsigonis; Mohammed Al-Hamadani; Jared H Linebarger; Choua A Vang; Forrest J Krause; Jeanne M Johnson; Edward Marchese; Kristen A Marcou; Jane M Hudak; Jeffrey Landercasper Journal: Reg Anesth Pain Med Date: 2016 May-Jun Impact factor: 6.288
Authors: Frances E Lennon; Tamara Mirzapoiazova; Bolot Mambetsariev; Ravi Salgia; Jonathan Moss; Patrick A Singleton Journal: Anesthesiology Date: 2012-04 Impact factor: 7.892
Authors: Daphna M Finn; Brian M Ilfeld; Jonathan T Unkart; Sarah J Madison; Preetham J Suresh; Nav Parkash S Sandhu; Nicholas J Kormylo; Nisha Malhotra; Vanessa J Loland; Mark S Wallace; Cindy H Wen; Anya C Morgan; Anne M Wallace Journal: J Anesth Date: 2017-03-31 Impact factor: 2.078
Authors: Dylan Zylla; Brett L Gourley; Derek Vang; Scott Jackson; Sonja Boatman; Bruce Lindgren; Michael A Kuskowski; Chap Le; Kalpna Gupta; Pankaj Gupta Journal: Cancer Date: 2013-09-16 Impact factor: 6.860
Authors: Jonathan B Yuval; Jasme Lee; Fan Wu; Hannah M Thompson; Floris S Verheij; Hersh V Gupta; Takeshi Irie; Joseph R Scarpa; Patrick J McCormick; J Joshua Smith; Jinru Shia; Martin R Weiser; Francisco Sánchez-Vega; Kay See Tan; Gregory W Fischer; Julio Garcia-Aguilar; Joshua S Mincer Journal: Br J Anaesth Date: 2022-06-17 Impact factor: 11.719
Authors: James G Connolly; Kay See Tan; Brooke Mastrogiacomo; Joseph Dycoco; Raul Caso; Gregory D Jones; Patrick J McCormick; Francisco Sanchez-Vega; Takeshi Irie; Joseph R Scarpa; Hersh V Gupta; Prasad S Adusumilli; Gaetano Rocco; James M Isbell; Matthew J Bott; Gregory W Fischer; David R Jones; Joshua S Mincer Journal: Br J Anaesth Date: 2021-07 Impact factor: 11.719